Compounding Labs

Investment partnership building long-term serial acquisition holding companies

[Compounding Labs @CompoundingLabs]

At Compounding Labs (CL), our approach to company building is distinctly (maybe even radically) different from the so-called private equity “model.” The product of many years of lived experience, it is happily iconoclastic and, as Henry Singleton would say, “it is NOT copied.”

[Compounding Labs @CompoundingLabs]

Over the coming decades, we aim to build a family of super-compounding, serial acquisition holding companies.

If the principles above resonated and you find this somewhat unusual lexicon intriguing, consider joining the movement by reaching out to [email protected].

We look forward to hearing from you!

[Compounding Labs @CompoundingLabs]

At Compounding Labs (CL), our approach to company building is distinctly (maybe even radically) different from the so-called private equity “model.” The product of many years of lived experience, it is happily iconoclastic and, as Henry Singleton would say, “it is NOT copied.”

[Compounding Labs @CompoundingLabs]

Ambition-
Perhaps the biggest difference from our peers is in the boldness of our aspirations. Measured by targeted net multiples of invested capital, we are unabashedly ambitious. While most of our private equity compatriots shoot for MOICs of 3-4x, we aspire to (and in some cases have already hit) triple-digit MOICs (not a misprint).